Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020
January 09 2020 - 8:00AM
Aprea Therapeutics, Inc. (NASDAQ: APRE), a biopharmaceutical
company focused on developing and commercializing novel cancer
therapeutics that reactivate mutant tumor suppressor protein p53,
today announced that Christian S. Schade, President & Chief
Executive Officer, will present a corporate update at the 38th
Annual J.P. Morgan Healthcare Conference on Tuesday, January 14,
2020 at 3:30 p.m. PT (6:30 p.m. ET).
A live webcast of the presentation can be
accessed from "Events Calendar" in the News and Events section of
the Aprea website at Link.
About Aprea Therapeutics, Inc.
Aprea Therapeutics Inc., (NASDAQ: APRE) is a
biopharmaceutical company headquartered in Boston, Massachusetts
with research facilities in Stockholm, Sweden, focused on
developing and commercializing novel cancer therapeutics that
reactivate mutant tumor suppressor protein, p53. The Company’s lead
product candidate is APR-246, a small molecule in clinical
development for hematologic malignancies, including myelodysplastic
syndromes (MDS) and acute myeloid leukemia (AML).For more
information, please visit the company website at
www.aprea.com.
Forward Looking Statements
This press release includes forward-looking
statements within the meaning of the federal securities laws.
Forward-looking statements involve known and unknown risks,
uncertainties, assumptions and other factors that may cause our
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. The
forward-looking statements contained in this press release reflect
Aprea’s current views with respect to future events, and Aprea does
not undertake and specifically disclaims any obligation to update
any forward-looking statements.
Source: Aprea Therapeutics
Corporate Contacts:
Scott M. CoianteSr. Vice President and Chief Financial
Officer617-463-9385
Gregory A. Korbel, Ph.D.Vice President of Business
Development617-463-9385
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aprea Therapeutics (NASDAQ:APRE)
Historical Stock Chart
From Jul 2023 to Jul 2024